05:21 , Mar 3, 2017 |  BC Week In Review  |  Company News

Pieris, Aska deal

Pieris granted Aska an exclusive option to develop and commercialize PRS-080 in Japan, South Korea and undisclosed other Asian markets outside of China. Pieris will receive $2.8 million up front. If the option is exercised,...
21:07 , Jan 27, 2017 |  BC Week In Review  |  Company News

TesoRx, Aska deal

TesoRx granted Aska an exclusive option to develop and commercialize THG-1001 in Japan. TesoRx will receive an undisclosed upfront payment and is eligible for milestones and royalties. THG-1001, an oral testosterone replacement therapy containing testosterone...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Fibristal ulipristal acetate regulatory update

Actavis said Health Canada approved Fibristal ulipristal acetate to treat moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery. The company plans to launch...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

Esmya ulipristal acetate: Phase III started

Watson began a double-blind, U.S. Phase III trial to compare 10 mg Esmya plus iron vs. placebo plus iron in about 300 women with anemia associated with uterine fibroids who are planning a hysterectomy or...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Clinical News

Esmya ulipristal acetate regulatory update

The European Commission approved an MAA for Esmya ulipristal acetate from PregLem S.A. to treat moderate to severe uterine fibroids in women of reproductive age. PregLem is part of Gedeon Richter. Richter gained the selective...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

Esmya ulipristal acetate: Additional Phase III data

Additional data from the double-blind, international Phase III PEARL II trial in 307 patients showed that once-daily 5 and 10 mg Esmya controlled uterine bleeding, the primary endpoint, in 90% and 98% of patients, respectively,...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

Esmya ulipristal acetate: Additional Phase III data

Additional data from the double-blind, international Phase III PEARL I trial in 242 patients showed once-daily 5 and 10 mg Esmya controlled uterine bleeding, a co-primary endpoint, in 91% and 92% of patients, respectively, at...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

Esmya ulipristal Acetate regulatory update

EMA's CHMP issued a positive opinion recommending approval of Esmya ulipristal acetate from Gedeon's Richter's PregLem S.A. subsidiary to treat moderate to severe uterine fibroids in women of reproductive age. Esmya is a selective progesterone...
07:00 , May 30, 2011 |  BC Week In Review  |  Company News

Aska Pharmaceutical, Sosei sales and marketing update

Sosei's Sosei Co. Ltd. subsidiary and its commercialization partner Aska Pharmaceutical launched NorLevo levonorgestrel in Japan as an emergency contraceptive. The wholesale acquisition price is not disclosed. Japan's Ministry of Health, Labor and Welfare (MHLW)...
07:00 , May 30, 2011 |  BC Week In Review  |  Company News

HRA Pharma, Aska Pharmaceutical sales and marketing update

HRA Pharma granted Aska exclusive rights to develop and commercialize ulipristal acetate in Japan. HRA Pharma already markets the selective progesterone receptor modulator (SPRM), which is approved as an emergency contraceptive, in EU as ellaOne...